ProRx Pharma has announced the addition of six injectable products to its portfolio, aimed at supporting the growing demand ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

As demand for GLP-1 medications surges, Hydreight’s inclusion of Liraglutide introduces a stable, patent-free, and clinically proven option—ideal for patients and providers seeking consistent ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

The following is a summary of “Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and ...

Exelan expects resupply in the second half of 2025, while Teva anticipates early April 2025. Cipla, Lupin and Takeda currently have alternative products available. Liraglutide injection: Multiple ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold under the brand names Victoza and Saxenda. Read on for everything ...